RYTM
Rhythm Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$102.63
−2.15%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−37.1x
Market Cap
$7.07B
MomentumView details →
1D Return
−2.15%
YTD Return
−4.27%
RSI (14)
37.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−37.1x
Market Cap
$7.07B
RSI (14)
37.5
MomentumView details →
1D Return
−2.15%
YTD Return
−4.27%
SummaryUpdated Jun 1, 2026
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company founded in 2008 and headquartered in Boston, Massachusetts. The company went public in October 2017 and focuses exclusively on developing and commercializing therapeutics for rare genetic diseases of obesity. Rhythm has successfully transitioned from a development-stage company to a commercial enterprise with its flagship product IMCIVREE, which targets specific genetic pathways that control hunger and weight regulation. The company operates in the highly specialized field of rare genetic obesity disorders, serving patients with conditions that were previously considered untreatable.
Similar companies
Latest newsMore news →
Rhythm Pharmaceuticals appointed Manher (AJ) Joshi as Chief Medical Officer, effective August 17, 2026.18d agoRhythm Pharmaceuticals announced preliminary data from an ongoing mid-stage study showing its experimental weekly injectable drug reduced body weight in patients with a rare form of obesity caused by brain damage.31d agoRhythm Pharmaceuticals reported second quarter 2026 net product revenue of $71.3 million from global sales of IMCIVREE.31d ago